NASDAQ
36.34USD
+1.22 (+3.47%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
26.3B
P/E
—
EPS
—
Beta
1.11
52W range
10.9-37
Day range
35.62–36.44
Open
35.88
Prev close
35.12
Volume
6.7M
Avg volume
5.8M
Dividend
0.00
IPO
2020-12-08
https://seekingalpha.com/article/4933728-roivant-sciences-the-balance-sheet-has-become-a-strategic-weapon · 8/8/2026+0.90
https://seekingalpha.com/article/4913538-roivant-sciences-ltd-roiv-presents-at-goldman-sachs-47th-annual-global-healthcare-conference · 6/10/2026+0.00
https://www.barrons.com/articles/immunovant-stock-trial-data-earnings-8bb5bfd7 · 5/20/2026+1.00
https://www.defenseworld.net/2026/04/12/elevate-capital-advisors-llc-sells-36236-shares-of-roivant-sciences-ltd-roiv.html · 4/12/2026+0.40
https://www.defenseworld.net/2026/04/04/top-green-energy-stocks-worth-watching-april-2nd.html · 4/4/2026+0.10
https://www.defenseworld.net/2026/04/04/roivant-sciences-adds-brepocitinib-lpp-trial-as-batoclimab-misses-phase-iii-ted-endpoint.html · 4/4/2026+0.20
https://www.defenseworld.net/2026/03/21/anderson-hoagland-co-has-22-12-million-position-in-eli-lilly-and-company-lly.html · 3/21/2026+0.40
https://seekingalpha.com/article/4881106-roivant-sciences-ltd-roiv-presents-at-leerink-global-healthcare-conference-2026-transcript · 3/11/2026+0.00
https://seekingalpha.com/article/4877677-roivant-sciences-ltd-roiv-presents-at-td-cowen-46th-annual-health-care-conference-transcript · 3/3/2026+0.10
https://www.defenseworld.net/2026/02/08/roivant-sciences-nasdaqroiv-sets-new-1-year-high-whats-next.html · 2/8/2026+0.80
https://seekingalpha.com/article/4867361-roivant-the-next-telavant-has-arrived-with-brepocitinibs-blockbuster-data-upgrade · 2/7/2026+1.00
https://www.defenseworld.net/2026/01/18/novaccess-global-otcmktsxsnx-versus-roivant-sciences-nasdaqroiv-financial-review.html · 1/18/2026+0.00
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
